Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

aspen veterinary resources, ltd. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin injectable is indcated fot he treatmen of infectious forms of arthritis caused by organisms sensitive to its activity. this includes most of the organisms responsible for the various infectious arthritides in swine, such as staphylococci, streptococci, erysipelothrix and mycoplasma ssp . it is also indicated for the treatment of mycoplasma pneumonia. as with all drugs, the use of lincomycin injectable is contraindicated in animals previously found to be hypersensitive to the drug. 

Kenija - engleski - Pharmacy and Poisons Board

gracure pharmaceuticals ltd e-1105 riico industrial area phase iii bhiwadi - lincomycin - capsule - lincomycin 500mg capsules - antibacterials for systemic use: lincosamides

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

mwi veterinary supply, inc. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - indicated for the treatment of arthritis caused by susceptible organisms and for mycoplasma pneumonia. lincomycin injectable is indicated for the treatment of infectious forms of arthritis caused by organisms sensitive to its activity. this includes most of the organisms responsible for the various infectious arthritides in swine, such as staphylococci, streptococci, erysipelothrix and mycoplasma spp .  it is also indicated for the treatment of mycoplasma pneumonia. as with all drugs, the use of lincomycin injectable is contraindicated in animals previously found to be hypersensitive to the drug.

Irska - engleski - HPRA (Health Products Regulatory Authority)

zoetis belgium s.a. - lincomycin hydrochloride - powder for use in drinking water - 400 milligram(s)/gram - lincomycin - pigs - antibacterial

Australija - engleski - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - clindamycin hydrochloride, quantity: 162.87 mg (equivalent: clindamycin, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; purified talc; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate; carmoisine; patent blue v - clindamycin bnm (clindamycin hydrochloride) capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.,clindamycin bnm capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. ,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. ,anaerobes serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. ,streptococci serious respiratory tract infections; serious skin and skin structure infections, septicaemia. ,staphylococci serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis. ,pneumococci serious respiratory tract infections. ,adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. indicated surgical procedures should be performed in conjunction with antibiotic therapy. ,bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - clindamycin hydrochloride, quantity: 162.87 mg - capsule, hard - excipient ingredients: shellac; magnesium stearate; titanium dioxide; iron oxide black; purified talc; maize starch; lactose monohydrate; gelatin; propylene glycol; strong ammonia solution - clindamycin hydrochloride capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. streptococci serious respiratory tract infections; serious skin and skin structure infections, septicaemia. staphylococci serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis. pneumococci serious respiratory tract infections. adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. indicated surgical procedures should be performed in conjunction with antibiotic therapy. bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - clindamycin hydrochloride, quantity: 162.87 mg - capsule, hard - excipient ingredients: maize starch; titanium dioxide; lactose monohydrate; gelatin; iron oxide black; shellac; magnesium stearate; purified talc - clindamycin hydrochloride capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. streptococci serious respiratory tract infections; serious skin and skin structure infections, septicaemia. staphylococci serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis. pneumococci serious respiratory tract infections. adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. indicated surgical procedures should be performed in conjunction with antibiotic therapy. bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clindamycin hydrochloride, quantity: 177.515 mg (equivalent: clindamycin, qty 150 mg) - capsule, hard - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; magnesium stearate; gelatin; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; iron oxide black; shellac; sulfuric acid; ammonia; dimeticone 1510; lecithin; ethanol; strong ammonia solution; potassium hydroxide - indications as at 20 june 2005 : dalacin c clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. dalacin c clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin - allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes - serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. streptococci - serious respiratory tract infections; serious ski

Irska - engleski - HPRA (Health Products Regulatory Authority)

ecuphar veterinaria s.l.u. - lincomycin (as lincomycin hydrochloride) - oral solution - 400 milligram(s)/millilitre - lincomycin - chickens - antibacterial

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

aspen veterinary resources - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - indications for swine: lincomycin 300 is indicated for the treatment of infectious forms of arthritis caused by organisms sensitive to its activity. this includes most of the organisms responsible for the various infectious arthritides in swine, such as staphylococci, streptococci, erysipelothrix and mycoplasma spp. it is also indicated for the treatment of mycoplasma pneumonia. contraindications: as with all drugs, the use of lincomycin 300 is contraindicated in animals previously found to be hypersensitive to the drug. human warnings: not for human use. keep out of reach of children.